Condition: Hyperandrogenism · Polycystic Ovary Syndrome · Puberty · Sponsor: University of Virginia
The purpose of this study is to determine if, in mid- to late pubertal girls with hyperandrogenism (HA), androgen-receptor blockade (spironolactone) alone normalizes sleep-wake luteinizing hormone (LH) pulse frequency (primary endpoint) and overall LH and follicle-stimulating hormone secretion (secondary endpoints).
This description comes directly from the study's public registry record.
Melissa Gilrain, BS · 434-243-6911 · mg7zb@hscmail.mcc.virginia.edu
Christine Burt Solorzano, MD · 434-243-6911 · cmb6w@hscmail.mcc.virginia.edu
Always discuss trial participation with your own doctor first.
| Center for Research in Reproduction, University of Virginia | Charlottesville, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04723862